Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
AIDS Research and Therapy|April 6, 2025
Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a reviewSharana Mahomed, Kayla Pillay, Razia Hassan-Moosa, et al.
PLOS Global Public Health|March 16, 2026
Quality assessment of data for decentralised antiretroviral therapy referrals and laboratory results in the South African national electronic HIV management register TIER.NetLisanthini Naidu, Johan van der Molen, Vishen Jugathpal, et al.
BMJ Open|July 6, 2019
Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trialSharana Mahomed, Nigel Garrett, Edmund Capparelli, et al.
Nature Communications|September 1, 2025
Hyaluronidase-enhanced subcutaneous delivery of bNAbs: a phase 1 randomized controlled clinical trial in HIV-uninfected womenSharana Mahomed, Farzana Osman, Martin Beliveau, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 12, 2026
Comparing clinical and cytokine profiling of genital inflammation as predictors of HIV acquisition in womenFarzana Osman, Nonhlanhla Yende-Zuma, Temesgen Zewotir, et al.
The Journal of Antimicrobial Chemotherapy|June 3, 2025
Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in womenSharana Mahomed, Martin Beliveau, Roberto Heredia-Ortiz, et al.
Frontiers in Immunology|December 23, 2022
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 preventionQuarraisha Abdool Karim, Derseree Archary, Françoise Barré-Sinoussi, et al.
BMJ Open|November 27, 2020
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trialSharana Mahomed, Nigel Garrett, Quarraisha A Karim, et al.
Medrxiv : the Preprint Server for Health Sciences|September 29, 2025
Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibodySharana Mahomed, Nonhlanhla N Mkhize, Leonid A Serebryannyy, et al.
The Lancet. HIV|March 31, 2023
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trialSharana Mahomed, Nigel Garrett, Edmund V Capparelli, et al.
Pageof 4